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Abstract
Of more than 150,000 published studies evaluating new biomarkers, fewer than 100 biomarkers
have been implemented for patient care[1]. One reason for this is lack of rigorous testing by the
medical community to validate claims for biomarker clinical relevance, and potential reluctance to
publish negative results when confirmation is not obtained. Here we sought to determine the utility
and reproducibility of immunohistochemical detection of hepatocyte growth factor (HGF) in
melanoma tissue, an approach of potential assistance in defining patients with innate resistance to
BRAF inhibitor therapy[2]. To this end, a published and a revised method that retained sensitivity
but with greater specificity for HGF detection, were evaluated in cells known to endogenously
express HGF, models where HGF is upregulated via cytokine induction, and via overexpression
by gene transfection. Consequent patient evaluation in collaboration with the Melanoma Institute
Australia of a cohort of 41 melanoma specimens with extensive clinical annotation failed to
validate HGF immunohistochemistry as a predictor of response to BRAF inhibitors. Targeted
therapies for advanced melanoma[3–5] and other cancers show great promise, and rigorous
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validation studies are thus indicated for approaches that seek to personalize such therapies in order
to maximize therapeutic efficacy.
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HGF; melanoma; biomarker; RAF-inhibitor
Introduction
A critical determinant of effective deployment of recent promising treatments for advanced
cancer is the use of tissue biomarkers that identify specific molecular and genomic targets or
mediators of therapeutic resistance. Before a biomarker can be applied to personalize
therapeutic approaches, rigorous validation is required[6]. An example of a potentially
important mediator of cancer resistance to targeted therapy is the hepatocyte growth factor
(HGF), which in vitro reactivates the mitogen-activated protein kinase (MAPK) pathway, a
driver of BRAF-mutant melanoma progression, resulting in resistance to BRAF inhibitor
therapy.[2, 7] It has been suggested[2] that the tumor microenvironment of metastatic
melanoma elicits innate resistance to RAF inhibitors through the secretion of HGF. Early
results indicate that RAF inhibitor therapy has the impressive ability to induce regression in
BRAF-mutant metastatic melanoma,[4, 8–10] an otherwise fatal form of cancer, via
inhibition of the MAPK pathway.[11–13] Thus, the ability of melanoma stromal cells, often
few in number and located at the periphery of relatively large metastatic nodules, to
counteract such treatment effects via HGF would have major implications for the potency of
the peritumoral cancer niche in conferring resistance to current targeted therapies. Moreover,
the prospect that immunohistochemical detection of any mediator in peritumoral stroma of
melanoma metastases predicts patients that are either responsive or resistant to RAF
inhibitors has major and pressing clinical implications for the use of such biomarkers in the
field of personalized medicine. We thus sought to explore further the practical utility of
HGF immunohistochemistry in defining candidates for RAF inhibitor therapy.
Materials and Methods
Cell Lines and Cell Culture
Human skin fibroblasts R2F1 (gift from Professor James G. Rheinwald, Brigham and
Women’s Hospital and Harvard Medical School) were originally isolated from infant
foreskin and cultured in a 1:1 mixture of M199 and M106 supplemented with 15% FBS, 10
ng/ml EGF, and 0.4 µg/ml hydrocortisone.
Viable cells were counted by Trypan blue exclusion assay under a hemocytometer.
HGF Overexpression
Stable overexpression of human HGF in fibroblasts was achieved using a retrovirus-based
approach.[14] Retroviral particles were produced in HK293 cells by co-transfecting
packaging vectors pCMV-VSV-G and pUMVC3 with HGF expressing vector (pBabe-puro
HGF, plasmid 10901; Addgene, Cambridge, MA) or its control vector pBabe-puro (plasmid
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1764, Addgene) as previous reported.[15] Viral supernatants were collected, filtered through
0.45µ m sterile filter, and added together with polybrene (8 mg/ml) to fibroblasts. Cells were
selected with puromycin (1 mg/ml) starting at 48 hours post transfection. Manipulation of
HGF levels was validated by quantitative RT-PCR and Western blot, and low-passage cell
culture (passages≤12) were used for all experiments.
Quantitative RT-PCR
Total mRNA was extracted from subconfluent cell cultures using RNeasy Mini kit (Qiagen
Valencia, CA), and first-strand cDNA was synthesized using High Capacity RNA-to-cDNA
kit (Applied Biosystems; Life Technologies, Carlsbad, CA). HGF expression was quantified
using HGF mRNA-specific primers (forward: TGATACCACACGAACACAGCTTTT;
reverse: TCCATGAGACCTCGATAACTCTCC), with SYBR master mix (Qiagen) in 7300
Realtime PCR system (Applied Biosystems; Life Technologies) and calculated with ΔΔCt
method.
Western Blotting
Cell culture medium (20 µl, equivalent to 2×105 viable cells/ml) was loaded to native, non-
denaturing SDS-PAGE gel. Recombinant human HGF (rHGF), 0.1 µg, (PeProTech, Rocky
Hill, NJ) was loaded as positive control. Proteins were separated on SDS-PAGE at constant
100V for 3.5 hours, and transferred to PVDF membrane at constant 340mA for 1.5 hours at
4°C. Membrane was blocked with 5% non-fat milk in TBS-Tween 20 at room temperature
for 1 hour, incubated with 1µg/ml of goat anti-HGF polyclonal antibodies (R&D systems,
Minneapolis, MN) over night at 4° C, and incubated with HRP-conjugated anti-goat
antibodies (Vector Laboratories, Burlingame, CA) at room temperature for 1 hour.
Membrane was washed with TBS-Tween 20 for 5 minutes, 3 times at room temperature
between procedures. Signal was developed using chemiluminescent substrate (Thermo
Scientific, Rockford, IL) at room temperature for 5 minutes and detected by ChemiDOC
XRS+ imager (Bio-Rad Laboratories, Hercules, CA).
Normal Human Tissue and Tissue Culture
Normal human placenta was obtained from an electively terminated 9-week gestation, fixed
overnight in 10% formalin and embedded in paraffin. Discarded normal human skin was
acquired from a single abdominoplasty specimen, was trimmed to 1×0.5 cm sections and
cultured at 37°C for 48 hours in cell culture media (DMEM [Lonza, Walkersville, MD]/10%
FBS + 1% antibiotic-antimycotic [Gibco; Life Technologies]) alone and with 250UI/ml
IL-1β (PeProTech). A portion of the specimen prior to culture, and explants after culture
were fixed overnight in 10% formalin and embedded in paraffin.
All tissue was obtained according to IRB-approved protocols.
Patient Melanoma Samples
In conformity to IRB-approved protocol, clinically annotated patient BRAF-mutant
formalin-fixed paraffin-embedded melanomas were obtained from the Melanoma Institute
Australia (Sydney, AU). Twenty-three tumor samples corresponded to biopsies performed
before (pre) BRAF inhibitor therapy (dabrafenib, 19 patients; vemurafenib, 4) and eighteen
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to biopsies obtained after initiation of treatment (dabrafenib, 16 patients; vemurafenib, 2)
from tumors that were progressing on treatment and therefore resistant to BRAF inhibitor
therapy (prog). Response to therapy was defined according to the Response Evaluation
Criteria in Solid Tumors (RECIST).[16, 17] In order to maximize the likelihood of finding
significant differences in responses to BRAF inhibitor when comparing HGF
immunoreactivity, pre-treatment samples were selected to represent distant points in the
spectrum of patient response and accordingly were grouped as good (at least 60% tumor size
reduction) and poor (less than 20% tumor size reduction) responders to BRAF inhibitor.
Immunocytochemistry and Immunohistochemistry
Sensitivity and specificity of antibodies and staining protocols were established in three
ways: 1) by evaluation of positive control human tissue (placenta) for stromal HGF
reactivity;[18] 2) by assessment of HGF induction in dermal stromal cells after recombinant
Il-1β exposure in vitro;[19, 20] and 3) by examination of cultured fibroblasts (R2F1 cells)
transfected with HFG expressing vector. Two different immunohistochemical protocols
were employed. The first was identical to that described by Straussman et al.[2], and the
second consisted of a simplified protocol not involving a tertiary antibody in order to
eliminate or diminish non-specific background staining present in control tissues when using
the first staining protocol. Samples were incubated with 10% horse serum for 1 hour at room
temperature (~25°C) followed by overnight incubation at room temperature with 5 µg/ml
HGF specific antibody (R&D Systems) and subsequent incubation with alkaline
phosphatase (AP)-coupled horse anti-goat antibody (Vector Laboratories) for 1 hour at room
temperature. Signal detection was performed employing AP substrate Vector Red® (Vector
Laboratories). Detection of E-selectin in formalin-fixed paraffin-embedded human skin
explants was performed after deparaffinization and epitope retrieval achieved by heating
tissue sections in 1mM EDTA (pH 8.0) incubating sections with 2.6µg/ml E-selectin-
specific antibody (Neuromics, Edina, MN) overnight at room temperature and then for 2
hours with HRP-horse anti-mouse antibodies (Vector Laboratories). HRP substrate
NovaRed® (Vector Laboratories) was employed for immunoreactivity detection.
Assessment of HGF Expression by Immunohistochemistry
The immunohistochemistry results were first reviewed by one observer (CL) using the four-
tier system previously described[2] where a score of 0 indicates absence of staining; 1,
weak; 2, moderate; and 3 strong staining, either in stromal or in tumor cells. When samples
presented heterogeneity in staining intensity, score was given for the strongest reactivity
present. The extent of staining was graded in four categories (1 to 10%, 11–24%, 25 to 50%
and >50%) according to the proportion of stromal or melanoma cells that were positive
within each cell population. The time spent analyzing each slide ranged from 15 to 30
minutes. Slides were also analyzed by a second observer (GFM) to exclude significant inter-
observer variation and to establish consensus scoring.
Statistical Analysis
Two-sided t-tests were used for all comparisons. A p-value of < 0.05 was considered
significant. Data are reported as sample means with error bars representing the standard
error of the means.
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Results
We initially examined a previously reported[2] immunohistochemistry protocol and
evaluated its sensitivity and specificity in control cells and tissue with known HGF
expression status. Accordingly, we examined human fibroblasts (R2F1) genetically modified
to overexpress HGF, as confirmed by RT-PCR and Western blot analyses (Figure 1, A).
Strong immunoreactivity in the HGF-expressing cells was documented. However, vector
control cells and HGF-transfected cells incubated with isotype-matched irrelevant antibody
both revealed positive reactivity with this staining protocol (Figure 1B, top row). We next
examined human placenta employing this protocol and found HGF+ stromal cells in villous
cores, as previously described.[18] However, there was high background staining as well as
non-specific staining in isotype-matched irrelevant controls (Figure 1, C, top panel). Finally,
normal human skin exposed to recombinant IL-1β, an established inducer of HGF
expression in fibroblast cell lines,[19, 20] also showed high background staining as well as
binding to elastic fibers (Figure 1, D, top panels) a finding further substantiated in medium
only and normal skin controls (data not shown). As a result, the immunohistochemistry
protocol was modified to eliminate the use of a tertiary antibody and a detection system
(HRP-DAB) that could result in false positivity in melanoma samples due to presence of
natural chromagen (e.g. melanin). By this second approach, HGF-transfected fibroblasts
showed unequivocal positive immunoreactivity while vector and isotype-specific controls
remained negative (Figure 1B, bottom row). HGF+ stromal cells were present in villous
cores, and cytotrophoblasts remained appropriately negative, as previously described[18]
(Figure 1, C, bottom panel). Human skin exposed to IL-1β demonstrated induction of HGF
in stromal cells within the dermis, as previously documented[19, 20] (Figure 1, D, bottom
panels). Normal human skin showed minimal HGF immunoreactivity, compared to skin
explants exposed to media alone or IL-1β (Figure 1, E). E-selectin (E-sel) was positive in
skin cultured in IL-1β consistent with culture viability and metabolic responsiveness, as
previously described[21]. Intermediate HGF and E-selectin were also induced by media
alone, consistent with previous observations of endogenous IL-1β release in this culture
setting (data not shown).[21]
Employing the modified staining protocol that enhanced specificity and diminished false-
positivity, without sacrificing sensitivity, we next assessed HGF biomarker expression by
peri-tumoral stromal cells and melanoma cells from clinically-annotated patient samples
before BRAF inhibitor therapy (n=23) and after disease progression while on BRAF
inhibitor therapy (n=18). A four-tier scale previously described[2] was employed to assess
staining intensity as “negative”, “weak”, “moderate” or “strong”. The proportion of positive
cells was stratified in 1 to 10%, 11 to 24%, 25 to 50% and more than 50%. Four of 23 pre-
BRAF inhibitor samples had weak HGF positivity in peri-tumoral stromal cells, three of
them with <10% staining extent (Figure 2, A and Table 1). In 6 of the 23 pre-BRAF
inhibitor samples, HGF+melanoma cells were observed. Three of these cases showed both
HGF+ stromal and melanoma cells. Staining intensity in melanoma cells ranged from weak
(n=4), to moderate (n=1) to strong (n=1) (Figure 2, B and Table 1). The proportion of
HGF+melanoma cells represented up to 10% (n=2), between 11 and 24% (n=2), between 25
and 50% (n=1) and more than 50 % (n=1) of all tumor cells. Employing the RECIST
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system[16, 17] for evaluation of BRAF inhibitor response, we found no significant
differences in maximal tumor size reduction when comparing presence or absence of HGF
immunoreactivity in peri-tumoral stromal or melanoma cells themselves (Figure 2, C black
and white bars, respectively). Furthermore, no significant differences were found between
patients that had good (at least 60% tumor size reduction) and poor (less than 20% tumor
reduction) responses when compared with intensity or extent of HGF immunoreactivity in
peri-tumoral stromal cells or melanoma cells. (Figure 2, D and E, respectively; black
bars=stromal cells, white bars=melanoma cells).
Samples obtained from tumors that were progressing on BRAF inhibitor treatment (n=18)
were also evaluated. Nine of these cases had at least some HGF+ peri-tumoral stromal cells,
6 with weak staining and 3 with moderate staining. The proportion of positive peri-tumoral
stromal cells varied from less than 10% (n=6) to between 11 and 24% (n=3). Fourteen of 18
samples of progressing tumors had at least some HGF+ melanoma cells. The intensity of the
staining varied from weak (n=12) to moderate (n=2). The proportion of positive melanoma
cells varied from less than 10% (n=6), to 11 to 24% (n=4), to 25 to 50% (n=1) to more than
50% (n=3) (data not shown).
Seven patients had paired samples of pre-treatment and progressing on BRAF i therapy
tumor lesions. Four of them had at least 60% maximal response by RECIST; and three
patients, less than 20% tumor size reduction. When HGF expression in either stromal cells
or tumor cells was compared between pre and progression samples, there was a consistent
trend toward increased HGF expression in progressing lesions that was independent of
degree of therapeutic response and consistent within both HGF expression parameters
analyzed, intensity and percent area of reactivity (Figure 2, F and G, for good and poor
responders respectively; black bars=stromal cells, and white bars=melanoma cells; data for
percent area of reactivity not shown). This trend was non-statistically significant when good
and poor responders were analyzed separately, and reached statistical significance when
these groups were combined (Figure 2, H; black bars=stromal cells, and white
bars=melanoma cells).
Discussion
Here we show that biomarker detection of stromal or tumor HGF in pre-therapy specimens
of metastatic melanoma fails to predict response to RAF inhibitor therapy. Negative results
traditionally have been published and cited less than those that support a stated hypothesis,
and this trend has been averred potentially to produce skewing that may contribute to
scientific bias.[22] Indeed negative findings are becoming increasingly recognized as crucial
to scientific progress that is made possible only through rigorous self-correction.[23] It also
has been posited that the so-called 'decline effect', where discoveries may gradually diminish
over time as they are eventually repeated, may be fueled by limited incentive for more
immediate testing and validation that carries with it the potential to produce negative
outcomes.[24] With respect to biomarkers, Marchio[25] has emphasized that although great
emphasis has been given to discovery, technical validation assays have not been embraced
with equal enthusiasm, although the process of assay validation is critical for the clinical
introduction of any new biomarker. We therefore believe that findings such as those
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reported herein, while negative, ultimately may serve to accelerate progress toward refining
pathology-based approaches that seek to personalize novel therapies for metastatic
melanoma.
Lim et al.[26] have emphasized the critical need for fully appreciating technical and
experimental design complexities inherent to biomarker validation in human tissues. In our
study, reasons that might explain the disparate conclusions regarding the predictive value for
HGF melanoma stromal biomarker expression[2] include differences in 1) biospecimen
preservation and archiving, 2) detection systems employed, 3) treatment protocols, and
finally 4) the nature of the target antigen itself. Firstly, the Melanoma BioSpecimen Bank of
the Melanoma Institute Australia has been a source for collaborative research worldwide,
supplying a wide range of clinically-annotated biomaterials. Specimen procurement,
preparation protocols, and archiving methods are rigidly controlled, and the bioarchive
successfully has supported a number of recent melanoma findings, including those involving
sensitive detection of the SOX2 transcription factor and the epigenetic mark 5-
hydroxymethylcytosine (5-hmC).[15, 27] Second, the detection system that we employed
was developed to eliminate false positivity while retaining the ability to sensitively detect
HGF-expressing stromal and tumor cells, an approach fundamental to clinical biomarker
validation and application The use of multiple complementary positive control tissues and
cells is regarded as critical to the validation process of tissue biomarkers such as HGF, and
this component of our study may indeed account for results that differed from previous
reports. Third, our patient cohort was treated mainly with the BRAF inhibitor, dabrafenib,
rather than vemurafenib that was employed in previous studies[2] However, both have
similar potency for BRAFV600E inhibition, and treatment outcomes are similar.[8, 10, 28–
30] Moreover, the previous study found no differences in correlation of the impact of HGF
stromal expression in relationship to the use of different MAPK inhibitors.[2] Finally, HGF
is a secreted protein synthesized by tumor and stromal cells, as well as other cell types,
including hematopoietic cell lines and bone marrow stroma.[31, 32] Because protein
secretion is a dynamic process, detection of intracellular stores from a single cellular
microenvironment may not always be as reliable as quantification of levels in serum[7] that
likely reflect aggregate secretion from multiple sources.
Current therapeutic strategies focused on metastatic melanoma are seeking to target
immunosuppressive co-stimulatory molecules,[3, 33, 34] melanoma-initiating cells,[35] and
oncogenic pathways.[8, 28, 36] Despite early success, cancers appear to be able to thwart
therapy through new virulence mechanisms that evolve during treatment; recent examples
being increased expression of melanoma stem cells displaying the biomarker ABCB5 during
chemotherapy,[37] and upregulation of CD274 (PD-L1) in melanomas during BRAF
inhibitor treatment.[38] Our finding in the present study that HGF expression by tumor and
stromal cells is significantly enhanced at disease progression is potentially relevant to such
therapy-associated virulence acquisition by melanoma cells and requires further inquiry and
validation. The literature clearly supports a role for HGF and other tyrosine-kinase ligands
in conferring resistance to targeted therapies (such as inhibitors of the MAPK pathway), and
the in vitro findings of Straussman et al.[2] represent an important contribution to this
dataset.[7, 36, 39–47] Although our analysis clarifies the limited of applicability of the HGF
biomarker to melanoma stromal cells, it remains of key importance to continue to consider
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how HGF in the living patient affects the MAPK pathway, and how this may be most
reliably measured. In this regard, a recent study by Jubb and coworkers[48] examining the
potential value of immunohistochemical detection of the HGF receptor tyrosine kinase,
MET, in defining melanoma resistance to BRAF therapy failed to show prognostic
significance in terms of response rate, progression-free survival, or overall survival, and thus
is consistent with our data indicating limited applicability of markers of the HGF-MET
pathway in determining such therapeutic responses.
Integration of biomarkers into drug development and clinical trials requires quality
assurance and assay validation to establish standardized guidelines for broad spectrum
application.[1, 6, 49] Studies that seek to correlate compelling in vitro data with the
possibility of practical application to predict responses in patients represent novel and
exciting directions in deployment of personalized pathology-based techniques. Indeed, while
our study did not confirm the utility of immunohistochemical detection of stromal HGF as a
means of defining melanoma patients who are resistant to BRAF therapy, it in no way
diminishes the potentially key role of HGF in conferring such resistance, as suggested in the
important study by Straussman and colleagues.[2] In aggregate, in this report focusing on
HGF we more broadly seek to emphasize that with continued rigor in biomarker validation,
appreciation of the complementary value of both positive and negative findings, and
aggressive translation of basic mechanistic insights into practical therapeutic applications,
there will exist significant and imminent promise for ultimate control of melanoma once it
spreads beyond the primary site.
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Figure 1. Validation of immunohistochemistry protocol for HGF
A: Quantitative RT-PCR analysis (top) of R2F1 fibroblasts showing mRNA for control
vector (Vec) and HGF-expressing vector (HGF); Western blot (bottom) reveals band from
recombinant HGF (rHGF), transfected cell supernatant (HGF-trans), and vector control
(Vec). B: R2F1 transfected fibroblasts were stained for HGF applying the immunostaining
protocol proposed by Straussman et al. (top row). Note strong staining in HGF transfected
cells (HGF trans), strong staining in fibroblasts transfected with control vector (Vec control)
and also high background staining in the isotype-matched irrelevant control. A simplified
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staining protocol (bottom row) showed immunoreactivity only in HGF transfected
fibroblasts and not in vector control transfected cells; the isotype control was negative.
C: Human normal placenta stained with Straussman et al. method (upper panel) and with a
modified protocol that eliminates the tertiary antibody and uses an alkaline phosphatase
detection system with a red chromagen (lower panel); insets show cytotrophoblasts (lower
third) and mesenchymal cells D: Human normal skin exposed to IL-1β for 48 hours stained
for HGF following Straussman et al. (upper panels). Note the similarity at 400× between an
HGF+dermal cell (asterisk) and an elastic fiber (encircled, arrows point other fibers). Oil
immersion (1000×) microphotograph (inset) allows distinction between the otherwise
equivocal tissue components. Same sample of human skin exposed to IL-1β for 48 hours
stained for HGF using the modified protocol does not present elastic fiber staining that could
be misinterpreted as HGF+dermal cells (lower panels). E: Normal skin showed lightly
counterstained nuclei with minimal immunoreactivity (left column); skin cultured in media
alone and with IL-1β for 48 hours showed progressive increase in expression of HGF
(middle and right columns), with IL-1β–treated skin containing cells that showed maximal
(score 3) HGF immunoreactivity.
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Figure 2. HGF expression in BRAF mutant patient melanomas
A: Example of tumor HGF expression juxtaposed with negative stroma (left panel),
scattered stromal cells with weak (arrows) to moderate (encircled) stromal HGF reactivity
(right panel) [dashed line= tumor/stroma interface]. B: Example of tumor HGF grading (0–
3).
C: Correlation of mean maximal response to BRAF inhibitor with peri-tumoral stromal
(black bars) and melanoma cell (white bars) HGF expression in pre-treament samples. D:
Mean intensity of HGF immunoreactivity for peri-tumoral stromal (black bars) and
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melanoma cells (white bars) in pre-treatment biopsies of poor versus good responders. E:
Mean extent of HGF immunoreactivity for peri-tumoral stromal (black bars) and melanoma
cells (white bars) in pre-treatment biopsies of poor versus good responders. F–H: Mean
intensity of stromal cell HGF expression in good responders (F), in poor responders (G),
and in good and poor responders combined (H) before BRAF inhibitor therapy (Pre) and
upon progressive disease while on BRAF inhibitor (Prog). Note trend to an increase in HGF
expression in progressing lesions in both stromal (black bars) and tumor cells (white bars)
that reaches statistical significance when good and poor response groups are combined (H).
Data for extent of HGF immunoreactivity in peri-tumoral stromal and melanoma cells
before BRAF inhibitor therapy and upon progressive disease while on BRAF inhibitor
treatment showed similar trends for good and poor responders when analyzed separately; the
increase in HGF expression extent in progressing tumor samples reached statistical
significance when good and poor responder groups were combined (data not shown).
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